Effects of Enzyme Replacement in Gaucher's Disease

Status Completed

Clinical Trial Summary

Gaucher disease is a lysosomal storage disease resulting from glycocerebroside accumulation in macrophages due to a genetic deficiency of the enzyme glucocerebrosidase. It may occur in adults but occurs most severely in infants, in whom cerebroside also accumulates in neurons. Patients with Gaucher's disease experience enlargement of the liver and spleen and bone destruction. The condition is passed from generation to generation through autosomal recessive inheritance. There are actually three types of Gaucher's disease.

Type I is the most common form. It is a chronic non-neuronopathic form, meaning the disease does not affect nerve cells. The symptoms of type I can appear at any age.

Type II appears in infancy and usually results in death for the patient. Type II is an acute neuronopathic form and can affect the brain stem. It is the most severe form of the disease.

Type III is also neuronopathic, however it is subacute in nature. This means the course of the illness lies somewhere between long-term (chronic) and short-term (acute).

The purpose of this study is to examine the effects of enzyme replacement therapy on patients with Gaucher's disease, specifically those types directly affecting the nervous system (neuronopathic).

Patients with Gaucher's disease types II and III will be selected to participate in the study and receive enzyme replacement therapy. Patients participating will undergo a variety of tests to measure levels of hemoglobin concentration, liver volume, and spleen volume. Improvements in these measures will be compared other laboratory tests measuring the involvement of the nervous system.

Clinical Trial Description

The purpose of this study is to examine the effects of enzyme replacement therapy in patients with neuronopathic Gaucher's disease and to investigate the pathogenesis of their neurological signs and symptoms. Macrophage-targeted glucocerebrosidase will be administered by intravenous infusion under the supervision of the patient's private physician at an initial dosage of 60 to 120 IU per kg of body weight weekly or every other week. Patients will be categorized as treatment responders if they display a clinically significant increase in hemoglobin concentration and a reduction in hepatic or splenic volume. Improvement in these parameters over time will be correlated with measurements for metabolic encephalopathy and radiologic, electrophysiologic and psychometric measurements of neurological involvement. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00001289
Study type	Observational
Source	National Institutes of Health Clinical Center (CC)
Contact
Status	Completed
Phase	N/A
Start date	September 23, 1991
Completion date	March 3, 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00004488` - Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's Disease	Phase 2
Completed	`NCT00001410` - PEG-Glucocerebrosidase for the Treatment of Gaucher Disease	Phase 1
Recruiting	`NCT00004293` - Phase II Study of Glucocerebrosidase in Patients With Gaucher Disease	Phase 2
Completed	`NCT00004294` - Phase I Study of Retrovirally Mediated Transfer of the Human Glucocerebrosidase Gene Into Peripheral Blood Stem Cells for Autologous Transplantation in Patients With Type I Gaucher Disease	Phase 1
Completed	`NCT04656600` - Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ	Phase 4
Completed	`NCT01427517` - Intravenous N-acetylcysteine for the Treatment of Gaucher's Disease and Parkinson's Disease	Phase 1
Completed	`NCT00176904` - Stem Cell Transplant for Inborn Errors of Metabolism	Phase 2/Phase 3
Completed	`NCT00001234` - Gene Therapy for Gaucher's and Fabry Disease Using Viruses and Blood-Forming Cells	Phase 1
Completed	`NCT06188325` - A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers	Phase 1
Completed	`NCT00001416` - Bone Response to Enzyme Replacement in Gaucher's Disease	Phase 2
Completed	`NCT06193304` - A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth	Phase 1
Active, not recruiting	`NCT00005900` - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT01586455` - Human Placental-Derived Stem Cell Transplantation	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.